[PDF] frontiersin.org

[PDF][PDF] Efficacy of Osimertinib in EGFR-mutated advanced non-small-cell lung cancer with different T790M status following resistance to prior EGFR-TKIs: a systematic …

XF Yi, J Song, RL Gao, L Sun, ZX Wu, SL Zhang… - Frontiers in …, 2022 - frontiersin.org
Purpose Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-
small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This …
被引用次数：2 相关文章

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic …

XF Yi, J Song, RL Gao, L Sun, ZX Wu… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-
small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This …

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic …

XF Yi, J Song, RL Gao, L Sun, ZX Wu… - Frontiers in …, 2022 - europepmc.org
Purpose Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-
small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This …
[HTML] nih.gov

[HTML][HTML] Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A …

XF Yi, J Song, RL Gao, L Sun, ZX Wu… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Purpose Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-
small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This …